Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Satellos Bioscience Inc ICOTF


Primary Symbol: T.MSCL Alternate Symbol(s):  MSCLF

Satellos Bioscience Inc. is a Canada-based biotechnology company. The Company is engaged in developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders. The Company is focused on the research in muscle stem cell polarity into a proprietary discovery platform, called MyoReGenX, to identify degenerative muscle diseases where deficits in this process affect muscle regeneration and are amenable to therapeutic intervention. With this platform, the Company is building a pipeline of therapeutics to correct muscle stem cell polarity and promote the body’s innate muscle repair and regeneration process. The Company’s lead program is an oral, small molecule drug candidate in development as a potential disease-modifying treatment for Duchenne muscular dystrophy. It has wholly owned subsidiaries in Australia (Satellos Bioscience Australia Pty Ltd), in Canada (Amphotericin B Technologies, Inc.) and in Delaware, USA (Satellos Bioscience US, Inc.).


TSX:MSCL - Post by User

Comment by bootsncatson Jul 20, 2018 10:56am
57 Views
Post# 28344268

RE:RE:RE:RE:RE:Patience

RE:RE:RE:RE:RE:PatienceI haven't seen any evidence that they have moved into phase II trials. If you have, I would appreciate if you share it with me.

Let's say they are in phase II. It takes more than just a few months to complete such trial. It can take a upwards to a few years. The whole clinical trials process can take anywhere from 5-10 years from phase I all the way to III. It actually doesn't end there. There is technically a phase IV trial after the drug has been approved, which is for post-market studies. Because at that point it is released for public use and you would have a much larger population to study. This is where they look for rare side effects and potential black box warnings that didn't show up in the clinical trials.
<< Previous
Bullboard Posts
Next >>